Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi has signed a licensing pact with Glenmark Pharmaceuticals Limited India (GPL) subsidiary Glenmark Pharmaceuticals SA (GPSA) to develop and commercialize a monoclonal antibody, GBR 500 for the treatment of Crohn's disease and other chronic autoimmune disorders.
Subscribe to our email newsletter
GBR 500 is an antagonist of the VLA-2 (alpha2-beta1) integrin, a receptor that plays a role in lymphocyte adhesion at inflammation sites and in the downstream release of inflammatory cytokines.
As per the terms of the pact, Sanofi is responsible to a sum of $50m as an upfront payment to Glenmark, of which $25m will be paid upon closing of the transaction and $25m, which is contingent upon Sanofi’s positive assessment of certain data to be provided by Glenmark.
Sanofi is also responsible to pay a success-based development, regulatory and commercial milestones to Glenmark.
In addition, Glenmark is entitled to receive double-digit royalties on net sales of products commercialized under the license.
Sanofi will have exclusive marketing rights in North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay, and co-marketing or co-promotion rights in Brazil, Russia, Australia and New Zealand.
However, Glenmark will retain exclusive marketing rights in India and the rest of the world.
Sanofi Global Research and Development president Elias Zerhouni said GBR 500 brings an approach to Sanofi’s Immuno-Inflammation portfolio, which they believe may address a significant gap in treating Inflammatory Diseases which would be of huge benefit to patients.